{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:42:33Z","timestamp":1792057353107,"version":"4.4.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Anecdotal accounts suggest an increase in problems initiating buprenorphine (BUP) treatment among individuals using illicitly manufactured fentanyl. Limited empirical data illuminate these challenges.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the prevalence of clinician-reported problems initiating BUP treatment among patients using fentanyl and describe clinical strategies used to overcome engagement challenges.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n For this survey study, an online survey was pilot tested and refined with a convenience sample of physicians. The final survey included 96 items and took less than 15 minutes to complete. The survey queried patients\u2019 use of fentanyl, BUP induction problems (precipitated or prolonged withdrawal), strategies to overcome induction problems, clinician characteristics, and practice characteristics. Eligible clinicians initiated BUP for at least 10 patients with opioid use disorder in the past year and at least 1 patient in the past 90 days. The survey was live from June 2, 2023, to March 18, 2024.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The main outcome of interest was precipitated and\/or prolonged opioid withdrawal. Descriptive statistics are reported, and logistic regression was used to identify factors associated with BUP initiation problems.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A random sample of physicians and advanced practice clinicians in the US Drug Enforcement Administration (DEA) registrant dataset from October 2022 (n\u2009=\u20093141) were invited to participate; of 2485 eligible for inclusion, 649 (26.1%) completed the prescreen survey. Of 421 (64.9%) eligible to complete the survey, the final sample included 396 (94.1%) clinicians who completed at least 50% of the survey items. Of 390 participants, 284 (72.8%) reported problems when initiating BUP in patients using fentanyl, with 242 of 394 (61.4%) reporting patients\u2019 experiencing precipitated withdrawal. A total of 264 or 392 participants (67.3%) reported modifying their standard induction procedures, changing how they counsel patients, or changing both medication and counseling protocols. In multivariable modeling, clinicians were more likely to report problems initiating BUP in patients if they had a DEA waiver to treat more than 100 patients (OR, 1.92; 95% CI, 1.08-3.40), vs those waivered to treat fewer patients; if they reported at least 75% of their patients using fentanyl (OR, 6.31; 95% CI, 2.59-15.35), vs no patients; or if they inducted patients in noninpatient settings (OR, 2.79; 95% CI, 1.39-5.61), vs inpatient settings.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this survey study of clinician-reported problems initiating BUP treatment, clinicians working in high-volume noninpatient settings reported more problems initiating BUP in patients using fentanyl, and many reported changing their clinical practices in response to these problems. Further research is warranted to match alternate BUP induction strategies by clinical settings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.52136","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:00:21Z","timestamp":1767628821000},"page":"e2552136","source":"Crossref","is-referenced-by-count":10,"title":["Barriers to Buprenorphine Initiation in Patients Using Fentanyl"],"prefix":"10.1001","volume":"9","author":[{"given":"Sarah S.","family":"Kawasaki","sequence":"first","affiliation":[{"name":"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Liebschutz","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Murray-Krezan","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Center for Biostatistics and Qualitative Methodology, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen E.","family":"Switzer","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Nash","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwonho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Center for Biostatistics and Qualitative Methodology, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Winstanley","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"3","key":"zoi251389r1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"9","key":"zoi251389r2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"47","key":"zoi251389r3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.15585\/mmwr.mm7047a4","article-title":"Notes from the field: testing for nonprescribed fentanyl and percentage of positive test results among patients with opioid use disorder\u2014United States, 2019-2020.","volume":"70","author":"Niles","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"zoi251389r4","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1001\/jama.2020.17694","article-title":"Analysis of drug test results before and after the US declaration of a national emergency concerning the COVID-19 outbreak.","volume":"324","author":"Wainwright","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"zoi251389r5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis.","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"zoi251389r6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/wps.20846","article-title":"The epidemic of fentanyl misuse and overdoses: challenges and strategies.","volume":"20","author":"Volkow","year":"2021","journal-title":"World Psychiatry"},{"key":"zoi251389r7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A review: fentanyl and non-pharmaceutical fentanyls.","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"zoi251389r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108147","article-title":"Protracted renal clearance of fentanyl in persons with opioid use disorder.","volume":"214","author":"Huhn","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi251389r9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13722-020-0177-x","article-title":"Case report: Successful induction of buprenorphine\/naloxone using a microdosing schedule and assertive outreach.","volume":"15","author":"Rozylo","year":"2020","journal-title":"Addict Sci Clin Pract"},{"key":"zoi251389r10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl.","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"2","key":"zoi251389r11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/dar.13394","article-title":"Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: a case series.","volume":"41","author":"Shearer","year":"2022","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"zoi251389r12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/15563650.2022.2032730","article-title":"Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl.","volume":"60","author":"Spadaro","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"zoi251389r13","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl.","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"issue":"10241","key":"zoi251389r14","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(20)30852-7","article-title":"New directions in the treatment of opioid withdrawal.","volume":"395","author":"Srivastava","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"zoi251389r15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/ADM.0000000000001185","article-title":"Fentanyl absorption, distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl.","volume":"17","author":"Bird","year":"2023","journal-title":"J Addict Med"},{"issue":"6","key":"zoi251389r16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zoi251389r17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajad.13135","article-title":"Microinduction of buprenorphine\/naloxone: a review of the literature.","volume":"30","author":"Ahmed","year":"2021","journal-title":"Am J Addict"},{"issue":"4","key":"zoi251389r18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ADM.0000000000001296","article-title":"High-dose buprenorphine initiation: a scoping review.","volume":"18","author":"Wong","year":"2024","journal-title":"J Addict Med"},{"key":"zoi251389r19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drugalcdep.2017.04.004","article-title":"Increases in self-reported fentanyl use among a population entering drug treatment: the need for systematic surveillance of illicitly manufactured opioids.","volume":"177","author":"Cicero","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"zoi251389r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department-initiated buprenorphine clinical trial in the era of fentanyl.","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi251389r21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annemergmed.2023.08.327","article-title":"302 incidence of buprenorphine-precipitated withdrawal in emergency department patients with opioid use disorder in Philadelphia.","volume":"82","author":"Kilaru","year":"2023","journal-title":"Ann Emerg Med"},{"issue":"12","key":"zoi251389r22","first-page":"1","article-title":"Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017.","volume":"68","author":"Hedegaard","year":"2019","journal-title":"Natl Vital Stat Rep"},{"key":"zoi251389r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108314","article-title":"Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance.","volume":"216","author":"Shover","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi251389r24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s11606-008-0866-8","article-title":"Home buprenorphine\/naloxone induction in primary care.","volume":"24","author":"Lee","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi251389r26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.13069","article-title":"Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone.","volume":"30","author":"Antoine","year":"2021","journal-title":"Am J Addict"},{"issue":"2","key":"zoi251389r27","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/ADM.0000000000000864","article-title":"Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis.","volume":"16","author":"Button","year":"2022","journal-title":"J Addict Med"},{"issue":"7","key":"zoi251389r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder.","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi251389r29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jamasurg.2021.0543","article-title":"AAPOR reporting guidelines for survey studies.","volume":"156","author":"Pitt","year":"2021","journal-title":"JAMA Surg"},{"issue":"3","key":"zoi251389r31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment.","volume":"36","author":"Netherland","year":"2009","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"zoi251389r32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11606-008-0881-9","article-title":"Integrating buprenorphine treatment into office-based practice: a qualitative study.","volume":"24","author":"Barry","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"9","key":"zoi251389r33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.14423\/SMJ.0000000000001292","article-title":"Best practices for survey use in medical education: how to design, refine, and administer high-quality surveys.","volume":"114","author":"Nikiforova","year":"2021","journal-title":"South Med J"},{"key":"zoi251389r34","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1141980","article-title":"Operational definition of precipitated opioid withdrawal.","volume":"14","author":"Dunn","year":"2023","journal-title":"Front Psychiatry"},{"issue":"1","key":"zoi251389r35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jsat.2010.04.001","article-title":"Factors associated with complicated buprenorphine inductions.","volume":"39","author":"Whitley","year":"2010","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"zoi251389r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35895","article-title":"Buprenorphine-precipitated withdrawal among hospitalized patients using fentanyl.","volume":"7","author":"Thakrar","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi251389r38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/11319320-000000000-00000","article-title":"Multiple peaking phenomena in pharmacokinetic disposition.","volume":"49","author":"Davies","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"zoi251389r39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12954-023-00879-7","article-title":"Reducing the harms of xylazine: clinical approaches, research deficits, and public health context.","volume":"20","author":"Zagorski","year":"2023","journal-title":"Harm Reduct J"},{"issue":"10469","key":"zoi251389r40","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/S0140-6736(24)02663-1","article-title":"\u201cEven worse than fentanyls\u201d: nitazenes in the USA.","volume":"404","author":"Samarasekera","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"zoi251389r41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40688","article-title":"From antidepressant tianeptine to street drug ZaZa: a narrative review.","volume":"15","author":"Wagner","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"zoi251389r42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/ADM.0000000000001141","article-title":"Clinical presentations and treatment of phenibut toxicity and withdrawal: a systematic literature review.","volume":"17","author":"Weleff","year":"2023","journal-title":"J Addict Med"},{"key":"zoi251389r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103584","article-title":"Latent patterns of polysubstance use among people who use opioids: a systematic review.","volume":"102","author":"Karamouzian","year":"2022","journal-title":"Int J Drug Policy"},{"key":"zoi251389r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2022.208934","article-title":"Methamphetamine use and illicit opioid use during buprenorphine treatment.","volume":"151","author":"Kratina-Hathaway","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"7","key":"zoi251389r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.1982","article-title":"Characteristics and prescribing patterns of clinicians waivered to prescribe buprenorphine for opioid use disorder before and after release of new practice guidelines.","volume":"4","author":"Jones","year":"2023","journal-title":"JAMA Health Forum"},{"key":"zoi251389r25","volume-title":"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction","author":"Center for Substance Abuse Treatment","year":"2004"},{"key":"zoi251389r36","volume-title":"Stata Statistical Software: Release 18.5","author":"StataCorp","year":"2023"},{"key":"zoi251389r30","unstructured":"Office of Intergovernmental and External Affairs (IEA). HHS Regional Offices. HHS.gov. August 14, 2024. Accessed November 19, 2024. https:\/\/www.hhs.gov\/about\/agencies\/iea\/regional-offices\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843413\/kawasaki_2026_oi_251389_1766511677.28797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:00:23Z","timestamp":1767628823000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.52136","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}